ESTRELLA IMMUNOPHARMA HIGHLIGHTS ARTEMIS® T-CELL THERAPY DATA SELECTED FOR ASH 2026, DEMONSTRATING DEEP AND DURABLE LEUKEMIA RESPONSES AND SUPERIOR EXTRAMEDULLARY DISEASE CLEARANCE VERSUS CONVENTIONAL CAR-T IN PRECLINICAL MODELS

Reuters · 2d ago

Please log in to view news